Transmissible spongiform encephalopathy update and implications for blood safety

Clinics in Laboratory Medicine

Volumn 23, Issue 1, 2003, Pages 129-137

  Ricketts, Maura N ^a   Brown, Paul ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; HUMAN; MEDICAL PRACTICE; POLICY; PRION DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY;

EID: 0037366963     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00066-5     Document Type: Review

References (32)

1. Brown P, Cervanakova L, McShane LM, Barber P, Rubenstein R, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999;39:1169-78.
2. Will R, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-5.
3. Brown P. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. BMJ 2001;322:841-4.
4. Bradley R. BSE: transmission studies with particular reference to blood. In: Brown F, Cartwright T, Horaud F, Speiser JM, editors. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals: viral safety and regulatory aspects. Dev Biol (Basel) 1999;99:35-40.
5. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, et al. Transmission of prion diseases by blood transfusion. J Gen Vir 2002;83:2897-905.
6. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983;41:154-61.
7. Rohwer RG. Titre. distribution, and transmissibility of blood-borne TSE infectivity. Presented at the 6th Annual Meeting of the Cambridge Healthtech Institute, "Blood product safety: TSE, perception versus reality." MacLean, Virginia, February 13-15, 2000.
8. Brown P, Rohwer RG, Dunstan BS, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998;38:810-6.
9. Holada K, Vostal JG. Different levels of prion protein (PrPc) expression on hamster, mouse and human blood cells. Br J Haematol 2000;110:472-80.
10. Brown P. The pathogenesis of transmissible spongiform encephalopathy: routes to the brain and the erection of therapeutic barricades. Cell Mol Life Sci 2001;58:259-65.
11. Klein R, Duble LJ. Transmission of Creutzfeldt-Jakob disease by blood transfusion. Lancet 1993;341:205-7.
12. Créange A, Gray F, Cesaro P, et al. Creutzfeldt-Jakob disease after liver transplantation. Ann Neurol 1995;38:269-72.
13. Patry D, Curry B, Easton D, et al. Creutzfeldt-Jakob disease (CJD) after blood product transfusion from a donor with CJD. Neurology 1998;50:1872-3.
14. Ricketts MN, Cashman RN, Stratton EE, El Saadany S. Is Creutzfeldt-Jakob disease transmitted in blood?. Emerg Infect Dis 1997;3:155-63.
15. Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 2000;321:17-9.
16. Evatt B, Austin E, Barnhart L, et al. Surveillance for Creutzfeldt-Jakob disease among persons with haemophilia. Transfusion 1998;38:817-20.
17. Lee CA, Ironside JW, Bell JE, et al. Retrospective neuropathological review of prion disease in UK haemophiliac patients. Thromb Haemost 1998;80:909-11.
18. Heye N, Hensen S, Muller N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994;343:298-9.
19. Operskalski EA, Mosley JW. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1995;346:1224.
20. Sullivan M. Epidemiological studies of CJD and blood, blood components and derivatives. Report of transmissible spongiform encephalopathies advisory committee meeting, October 6-7, 1997. Washington, DC: Food and Drug Administration; 1997. Bethesda: US Department of Health and Human Services. 1997. p. 98-105.
21. Zerr I, Brandel J-P, Masullo C, et al. European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J Clin Epidemiol 2000;53:747-54.
22. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996;2:333-7.
23. Will RG, Kimberlin RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 1998;75:178-80.
24. Budka H, Pocchiari M, Aguzzi A, et al. Report on the safety of ruminant blood with respect to TSE risks, Paper presented at the meeting of the Scientific Steering Committee, Brussels, Germany, April 13-14, 2000.
25. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998;352:703-4.
26. Hill AF, Butterworth RJ, Jointer S, et al. Investigation of variant Creutzfeldt-Jakob and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183-99.
27. Lazmézas CI, Fournier J-G, Nouvel V, et al. Adaptation of the BSE agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci USA 2001;98:4142-7.
28. Warden J. Delay in plasma replacement. BMJ 1998;317:1409.
29. Busch MP, Glynn SA, Schreiber GB. Potential increased risk of virus transmission due to exclusion of older donors because of concern over Creutzfeldt-Jakob disease. The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 1997; 37:996-1002.
30. World Health Organization. Variant Creutzfeldt-Jakob disease (vCJD): precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion. Weekly Epidemiologic Record No. 47, 2000;75:377-8.
31. Brown P, Preece M, Brandel J-P, et al. Iatrogenic CJD at the millennium. Neurology 2000;55:1075-81.
32. Taylor DM, Fernie K, Reichl HE, Somerville RA. Infectivity in the blood of mice with BSE-derived agent. J Hosp Infect 2000;46:78-9.